Stocks and InvestingStocks and Investing
Wed, November 4, 2020
Tue, November 3, 2020
Mon, November 2, 2020
Sun, November 1, 2020
Fri, October 30, 2020

Gena Wang Maintained (VRTX) at Buy with Decreased Target to $307 on, Oct 30th, 2020


Published on 2024-10-27 14:35:05 - WOPRAI, Gena Wang
  Print publication without navigation


Gena Wang of Barclays, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Decreased Target from $315 to $307 on, Oct 30th, 2020.

Gena has made no other calls on VRTX in the last 4 months.



There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 1 agrees with Gena's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Decreased Target to $249 on, Monday, October 19th, 2020


These are the ratings of the 5 analyists that currently disagree with Gena


  • Colin Bristow of "UBS" Initiated at Strong Buy and Held Target at $287 on, Wednesday, October 28th, 2020
  • Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Decreased Target to $305 on, Thursday, October 15th, 2020
  • Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $305 on, Friday, July 31st, 2020
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $315 on, Friday, July 31st, 2020
  • Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $330 on, Thursday, July 2nd, 2020